DZD Doubles Down on epiXact® Service for Investigating HAI Outbreaks Supported by New NIH Funding Award
December 9 2020

SBIR Phase I Funds to Boost Speed of the Company’s Robust Sequencing and Analysis Service for Infection Control Professionals

Read More
DZD Announces High-Caliber Additions to Leadership Team and Advisory Board
November 17 2020

Dekel Gelbman joins as SVP, Business Development & Strategy, Robin Patel, M.D. joins DZD's clinical and scientific advisory board and Sally Hojvat, Ph.D. joins as a regulatory strategy advisor

Read More
DZD Announces Positive Data from Multiple Studies Demonstrating Promise of New Technology
October 21 2020

Initial results show new class of diagnostics can provide culture-free pathogen identification and drug-resistance profile within hours, not days

Read More
Day Zero Diagnostics Moves Headquarters to SmartLabs at Boston Landing
August 3 2020

Company now occupies over 9,000 square feet of cutting-edge office and lab space

Read More
DZD Research Highlighted in Two Publications on Plasmid-Mediated Antibiotic Resistance
June 2 2020

DZD technical expertise enables identification of novel mechanisms of antibiotic resistance using nanopore sequencing

Read More
DZD Awarded $6.2M Non-Dilutive Funding to Develop Rapid Antibiotic Resistance Diagnostic
May 11 2020

CARB-X selects Day Zero Diagnostics for their global portfolio of technologies to combat antibiotic-resistance

Read More